Enveda, a biotech company focused on discovering drugs derived from natural sources using artificial intelligence, has raised $311 million in a Series E funding round. This latest investment was led by Catalio Capital Management with participation from Iconiq and other investors, doubling the company's valuation to $2 billion within a year. Founded in 2019 by Viswa Colluru, formerly of Recursion Pharmaceuticals, Enveda aims to accelerate drug discovery by leveraging plants and microbes rather than relying solely on synthetic compounds.

The startup employs AI technologies to identify promising candidates from nature’s vast chemical diversity, speeding up the traditionally lengthy and costly process of drug development. Although AI-driven drug discovery has yet to yield FDA-approved treatments, Enveda is advancing several candidates into human clinical trials. Among these, Enveda is testing a drug for severe skin conditions and another aimed at supporting sustained weight loss after the cessation of GLP-1 medications.

Enveda’s approach represents a significant shift in the biotech landscape, combining ancient natural remedies with modern AI techniques to streamline the path to new therapeutics. This strategy not only opens new avenues for novel drugs but also reflects growing investor confidence in the integration of AI and natural product chemistry. The fresh capital injection will support expanding Enveda’s pipeline and scaling their platform to bring more nature-inspired medicines into later-stage clinical trials.

As AI continues to reshape drug discovery, Enveda stands out by focusing on nature-derived compounds, a niche with immense potential yet relatively underexplored by purely synthetic drug developers. With this substantial funding round and its current clinical-stage projects, Enveda is well-positioned to make meaningful contributions to the emerging field of AI-powered natural drug discovery over the next several years.